Paternal Metformin Use Not Linked to Major Congenital Malformations
By Elana Gotkine HealthDay Reporter
MONDAY, June 17, 2024 -- Paternal use of metformin in monotherapy is not associated with an increased risk for major congenital malformations (MCMs), according to a study published online June 18 in the Annals of Internal Medicine.
Ran S. Rotem, Sc.D., from the Harvard T.H. Chan School of Public Health in Boston, and colleagues examined the association between paternal metformin use during spermatogenesis and MCMs in newborns to assess the potential adverse intergenerational effect of metformin in a nationally representative cohort study. Data were included for 383,851 live births that occurred in 1999 to 2020.
The researchers found that the prevalence of cardiometabolic morbidity was substantially higher among fathers who used metformin during spermatogenesis and their spouses compared with unexposed fathers. The crude odds ratio for paternal metformin exposure in all formulations and MCMs was 1.28 (95 percent confidence interval, 1.01 to 1.64), but the odds ratio after adjustment was 1.00 (95 percent confidence interval, 0.76 to 1.31). The adjusted odds ratio was 0.86 (95 percent confidence interval, 0.60 to 1.23) and 1.36 (95 percent confidence interval, 1.00 to 1.85) for metformin in monotherapy and for metformin in polytherapy, respectively.
"Future research should examine the intergenerational effects of paternal cardiometabolic morbidity and related drug treatments while applying specific focus to polytherapies and aiming to disentangle potential drug-related effects from effects exerted by the underlying clinical indication," the authors write.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted June 2024
Read this next
Many Medicaid Enrollees Have Restricted Access to SGLT2 Inhibitors, GLP-1 Receptor Agonists
WEDNESDAY, April 30, 2025 -- Many Medicaid enrollees with type 2 diabetes have restricted access to cardioprotective medications, including sodium-glucose cotransporter-2...
Sodium-Glucose Cotransporter 2 Inhibitors Increase Risk for Falls in Patients With Diabetes
WEDNESDAY, April 30, 2025 -- Sodium-glucose cotransporter 2 (SGLT2) inhibitor use is an independent risk factor for falls in people with type 2 diabetes, according to a study...
USPSTF Recommends Counseling to Prevent Perinatal Depression
FRIDAY, April 25, 2025 -- The U.S. Preventive Services Task Force (USPSTF) recommends counseling for women at increased risk for perinatal depression (PND). This recommendation...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.